Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Obstructive sleep apnea (OSA) and outcomes from coronavirus disease 2019 (COVID-19) pneumonia: a systematic review and meta-analysis

Timotius Ivan Hariyanto a, Andree Kurniawan b, *

a Faculty of Medicine, Pelita Harapan University, Boulevard Jendral Sudirman Street, Karawaci, Tangerang, 15811, Indonesia
b Department of Internal Medicine, Faculty of Medicine, Pelita Harapan University, Boulevard Jendral Sudirman Street, Karawaci, Tangerang, 15811, Indonesia

ARTICLE INFO

Article history:
Received 12 December 2020
Received in revised form 4 February 2021
Accepted 25 March 2021
Available online 1 April 2021

Keywords:
Coronavirus disease 2019
COVID-19
Sleep apnea
Sleep disorder
OSA

ABSTRACT

Background: Obstructive sleep apnea (OSA) is the most prevalent sleep-related breathing disorder which could impair someone's quality of life and is also associated with poor outcomes from many diseases. Currently, the evidence regarding the link between OSA and coronavirus disease 2019 (COVID-19) is still conflicting. This study aims to analyze the relationship between OSA and poor outcomes of COVID-19.

Materials and methods: We systematically searched the PubMed and Europe PMC database using specific keywords related to our aims until December 10th, 2020. All articles published on COVID-19 and OSA were retrieved. The quality of the study was assessed using the Newcastle–Ottawa Scale (NOS) tool for observational studies. Statistical analysis was done using Review Manager 5.4 software.

Results: A total of 21 studies with 54,276 COVID-19 patients were included in this meta-analysis. This meta-analysis showed that OSA was associated with composite poor outcome [OR 1.72 (95% CI 1.55–1.91), p < 0.00001, I² = 36%, random-effect modeling] and its subgroup which comprised of severe COVID-19 [OR 1.70 (95% CI 1.18–2.45), p = 0.005], ICU admissions [OR 1.76 (95% CI 1.51–2.05), p < 0.00001], the need for mechanical ventilation [OR 1.67 (95% CI 1.48–1.88), p < 0.00001], and mortality [OR 1.74 (95% CI 1.39–2.19), p < 0.00001].

Conclusions: Extra care and close monitoring should be provided to patients with OSA to minimize the risk of infections. Simple questionnaires such as STOP-Bang questionnaire can be used for screening patients who may be at risk for severe adverse outcomes.

© 2021 Elsevier B.V. All rights reserved.

1. Introduction

Coronavirus disease 2019 (COVID-19) can have a wide variety of clinical manifestations, from mild respiratory symptoms such as fever, cough, and anosmia to severe-life threatening conditions such as respiratory distress, arrhythmia, sepsis, shock, and loss of consciousness [1,2]. Previously published meta-analysis studies have identified several comorbidities that were associated with severe outcomes from COVID-19, such as obesity, hypertension, diabetes, thyroid disease, dyslipidemia, cardiovascular disease, and pulmonary disease [3–10]. Among patients with obesity, one of the most prevalent co-existing comorbid conditions was obstructive sleep apnea (OSA). OSA is the most common sleep-related breathing disorder and is highly prevalent, possibly affecting up to 1 billion people around the world [11]. It is characterized by transient increases in upper airway resistance, causing reductions or interruption of the airflow accompanied by increased respiratory effort [12]. This condition can disrupt breathing during sleeping and make someone becomes awake during night time. As a result, people with OSA often experience severe daytime drowsiness, fatigue, irritability, having difficulty concentrating, and may have a higher risk of work-related accidents [13]. During the COVID-19 pandemic, many people experience difficulty in sleeping where their sleep quality has been significantly impaired because of high mental burden, changes in their daily routines, and feelings of helplessness, abandonment, loneliness, and fear [14]. The presence of OSA can make these matters even worse. Unfortunately, until now, the evidence regarding the link between OSA and COVID-19 is still conflicting. Several observational studies showed that the presence of OSA was associated with poor COVID-19 outcomes [15–17], but several others showed that OSA did not alter the outcomes of COVID-19 [18,19]. This article aims to explore and give
clear evidence regarding the potential association between OSA and poor outcomes of COVID-19.

2. Materials and methods

2.1. Eligibility criteria

Studies were included in this review if met the following inclusion criteria: Population: positive/confirmed cases of COVID-19; Intervention/Exposure: a group of patients with OSA as their comorbidity; Comparison/Control: a group of patients without OSA; Outcome: composite poor outcomes which comprise of severe COVID-19 and mortality) [20,21], type of study was a randomized control trial, cohort, clinical trial, case-cohort, and cross-over design, and if the full-text article was available. The following types of articles were excluded: articles other than original research (eg, review articles, letters, or commentaries); case reports; articles not in the English language; articles on research in pediatric populations (17 years of age or younger); and articles on research in pregnant women.

2.2. Search strategy and study selection

A systematic search of the literature was conducted on PubMed and Europe PMC using the keywords “sleep apnea syndrome” OR “obstructive sleep apnea” OR “OSA” AND “coronavirus disease 2019” OR “COVID-19,” between 2019 and the present time (December 10th, 2020) with language restricted to English only. The title, abstract, and full text of all articles identified that matched the search criteria were assessed, and those reporting the rate of OSA in COVID-19 patients with a clinically validated definition of each outcome of interest were included in this meta-analysis. The references of all identified studies were also analyzed (forward and backward citation tracking) to identify other potentially eligible articles. The study was carried out per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.

2.3. Data extraction and quality assessment

Data extraction was performed independently by two authors, we used standardized forms that include author, year, study design, number of participants, age, gender, hypertension, obesity, OSA, body mass index (BMI), and proportion of patients with each outcome of COVID-19.

The outcome of interest was the composite poor outcome that comprised of severe COVID-19, Intensive Care Unit (ICU) admission, the need for mechanical ventilation, and mortality. Severe COVID-19 was defined as patients who had any of the following features at the time of, or after, admission: (1) respiratory distress (≥30 breaths per min); (2) oxygen saturation at rest ≤93%; (3) ratio of the partial pressure of arterial oxygen (PaO2) to a fractional concentration of oxygen inspired air (fIO2) ≤300 mmHg; or (4) critical complication (respiratory failure, septic shock, and or multiple organ dysfunction/failure) [22]. ICU admission was defined as the patients who were admitted or transferred into the intensive care unit (ICU). The need of mechanical ventilation was defined as the patients who need a mechanical ventilator to assist their breathing. The mortality outcome from COVID-19 was defined as the number of patients who were dead because of COVID-19 infection.

Two investigators independently evaluated the quality of the included cohort and case–control studies using the Newcastle–Ottawa Scale (NOS) [23,24]. The selection, comparability, and exposure of each study were broadly assessed and studies were assigned a score from zero to nine. Studies with scores ≥7 were considered of good quality.

2.4. Statistical analysis

A meta-analysis was performed using Review Manager 5.4 (Cochrane Collaboration) software. We used the Generic Inverse Variance formula with random-effects models to calculate each outcome's risk. The heterogeneity was assessed by using the I2 statistic with a value of <25%, 25–50%, and >50% were considered as low, moderate, and high degrees of heterogeneity, respectively. The effect estimate was reported as odds ratio (OR) along with its 95% confidence intervals (CIs) for dichotomous variables, respectively. P-value was two-tailed, and the statistical significance was set at <0.05. Subgroup analysis was performed for each component of composite poor outcomes. We performed Beggs funnel-plot analysis to qualitatively assess the risk of publication bias.

3. Results

3.1. Study selection and characteristics

A total of 255 records were obtained through systematic electronic searches. After the removal of duplicates, 234 records remained. A total of 204 records were excluded after screening the titles/abstracts because they did not match our inclusion and exclusion criteria. After evaluating 30 full-texts for eligibility, 5 full-text articles were excluded because they do not have the outcome of interest (severe COVID-19, ICU admission, the need for mechanical ventilation, and mortality), 3 full-text articles were excluded because they do not have the control/comparison group, 1 full-text article was excluded because the articles were not in English, and finally, 21 studies [15–19,25–40] with a total of 54,276 COVID-19 patients and 4640 patients with OSA were included in the meta-analysis (Fig. 1). Of a total of 21 included studies, 19 were retrospective cohort, 1 study was a prospective cohort, while the remaining 1 study was a case–control study. The diagnosis of COVID-19 was confirmed by using Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) from respiratory tract swabs in all of the included studies. The essential characteristics of the included studies are summarized in Table 1.

3.2. Quality of study assessment

Studies with various study designs including cohort and case–control were included in this review and assessed accordingly with the appropriate scale or tool. Newcastle–Ottawa Scales (NOS) were used to assess the cohort and case–control studies (Table 2). All included studies were rated ‘good’. In conclusion, all studies were seemed fit to be included in the meta-analysis.

3.3. Obstructive sleep apnea (OSA) and outcomes

Our pooled analysis showed that OSA was associated with composite poor outcome [OR 1.72 (95% CI 1.55–1.91), p < 0.00001, I2 = 36%, random-effect modeling] (Fig. 2). Subgroup analysis showed that OSA was associated with severe COVID-19 [OR 1.70 (95% CI 1.18–2.45), p = 0.005, I2 = 53%, random-effect modeling], ICU admissions [OR 1.76 (95% CI 1.51–2.05), p < 0.00001, I2 = 0%, random-effect modeling], the need for mechanical ventilation [OR 1.67 (95% CI 1.48–1.88), p < 0.00001, I2 = 0%, random-effect modeling], and mortality from COVID-19 [OR 1.74 (95% CI 1.39–2.19), p < 0.00001, I2 = 48%, random-effect modeling].
3.4. Publication bias

The funnel-plot analysis showed a qualitatively symmetrical inverted funnel-plot for the association between OSA and composite poor outcome (Fig. 3), showing no indication of publication bias.

4. Discussion

Based on our pooled analysis of available data, obstructive sleep apnea (OSA) seems to be associated with an enhanced risk of severe COVID-19, ICU admission, the need for mechanical ventilation, and mortality from COVID-19 infection. Several reasons can be proposed to explain this result. First, most of the patients with obstructive sleep apnea (OSA) were overweight or obese and OSA itself is strongly associated with other comorbid conditions such as hypertension, cardiovascular disease, and diabetes [41]. As we know, obesity, hypertension, cardiovascular disease, and diabetes is also associated with severe COVID-19 and mortality outcomes from COVID-19 [3,6,10]. Second, repetitive episodes of complete/partial cessation of airflow or breathing during sleep which is frequently observed in patients with OSA, is associated with dysregulation of the renin–angiotensin system (RAS) pathway [42]. A published meta-analysis study has shown that higher levels of angiotensin II and aldosterone were observed in patients with OSA, regardless of patients with pre-existing hypertension [43]. Another study has also shown that patients with untreated OSA, regardless of the presence of hypertension, were associated with an increased angiotensin-converting enzyme (ACE) activity [44]. In addition, obesity, significant comorbidity in OSA patients, also influences the RAS [41]. On the other side, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, uses the angiotensin-converting enzyme 2 (ACE2) as their entry receptor into host cells. ACE2 is the nonclassical pathway of RAS, thus, RAS itself is involved in the pathogenesis of COVID-19 [42]. The dysregulation of RAS which is happened in patients with OSA can promote SARS-CoV-2 entry into host cells, increasing its viral load and infectivity, and finally resulting in the severe outcome and mortality of the disease. The dysregulation of RAS may also contribute to the increased prevalence of cardiovascular and cerebrovascular disease reported in OSA patients where all of those are associated with severity and mortality outcomes from COVID-19 [42,44]. Third, patients with OSA often have sleep deprivation because of frequent awakening during sleeping time. Sleep deprivation itself will increase the interleukin-6 (IL-6), interleukin-17 (IL-17), and tumor necrosis factor-α (TNF-α) which promote the inflammatory activity in neutrophils [45,46]. Elevation in the IL-6 and TNF-α levels have been implicated in severe COVID-19 cases, thus sleep deprivation in OSA could exacerbate the cytokine storm in COVID-19 which can cause acute respiratory distress syndrome (ARDS) and multiorgan failure [47]. Finally, repetitive airway collapse which happened in OSA not only causes dysregulation in RAS but also causes hypoxia during sleep. This resulting hypoxia from OSA could potentially contribute to worsening of the hypoxia in COVID-19 pneumonia and increase the likelihood of developing poor outcomes from COVID-19 [41].

This study has several limitations. First, data on the definition, duration, grading, and type of treatment for OSA patients were lacking in the included studies, hence, cannot be analyzed. Second, we include some pre-print studies to minimize the risk of publication bias, however, the authors have made exhaustive efforts to ensure that only sound studies were included and we expect that most of those studies currently available in pre-print form will eventually be published and that we will identify them through ongoing electronic literature surveillances. We hope that this study can give further insight into OSA in COVID-19 patients.
### Table 1
Characteristics of included studies.

| Study | Sample size | Design | Overall age mean ± SD | Male n (%) | Hypertension n (%) | Obesity n (%) | OSA n (%) | BMI | Outcome |
|-------|-------------|--------|-----------------------|------------|--------------------|---------------|-----------|-----|---------|
| Argenziano MG et al. [25] 2020 | 1000 | Retrospective cohort | 62.6 ± 18.5 | 596 (59.6%) | 601 (60.1%) | 352 (35.2%) | 24 (2.4%) | 28.9 ± 5.8 | ICU admission |
| Cade BE et al. [15] 2020 | 4668 | Cohort | 55.9 ± 22.6 | 2072 (44.4%) | N/A | N/A | 443 (9.5%) | 29.1 ± 5.7 | ICU admission, mechanical ventilation, mortality |
| Cariou B et al. [26] 2020 | 1317 | Retrospective cohort | 69.8 ± 13 | 855 (64.9%) | 1003 (76.1%) | 428 (38.3%) | 144 (10.9%) | 28.7 ± 5.7 | Mechanical ventilation, mortality |
| Dashit H et al. [27] 2020 (pre-print) | 4140 | Retrospective cohort | 51 ± 21.4 | 1863 (45%) | 910 (21.9%) | 1135 (27.4%) | 259 (6.2%) | 30 ± 7.8 | ICU admission, mortality |
| Dreher M et al. [28] 2020 | 50 | Retrospective cohort | 66.3 ± 13.3 | 33 (66%) | 35 (70%) | 17 (34%) | 7 (14%) | 28.3 ± 4.4 | Severe COVID-19 (respiratory distress) |
| Feuth T et al. [18] 2020 | 28 | Retrospective cohort | 58.3 ± 18.5 | 15 (54%) | 12 (43%) | 10 (35.7%) | 8 (29%) | 28.1 ± 4.9 | ICU admission |
| Goodall JW et al. [29] 2020 | 981 | Retrospective cohort | 68.3 ± 17.7 | 631 (64.3%) | 486 (49.6%) | N/A | 17 (1.7%) | N/A | Mortality |
| Gottlieb M et al. [30] | 2020 | Cohort | 41.3 ± 18.5 | 4045 (46.6%) | 1917 (22.1%) | 1290 (14.8%) | 288 (3.3%) | 27.2 ± 6.5 | Severe COVID-19 (respiratory distress) |
| Ioannou GN et al. [31] 2020 | 10,131 | Retrospective cohort | 63.6 ± 16.2 | 9221 (91%) | 6294 (62.1%) | 4542 (44.8%) | 2270 (26.8%) | N/A | Mechanical ventilation, mortality |
| Izquierdo JL et al. [32] 2020 | 10,504 | Retrospective cohort | 58.2 ± 19.7 | 5519 (52.5%) | 3527 (33.6%) | 936 (8.9%) | 212 (2%) | N/A | ICU admission |
| Jimenez E et al. [33] 2020 | 1549 | Retrospective cohort | 68.3 ± 19.2 | 890 (57.5%) | 851 (55%) | 240 (15.7%) | 79 (8.4%) | N/A | ICU admission, mortality |
| Kar A et al. [16] 2020 (pre-print) | 213 | Case-control | 54.3 ± 14.8 | 144 (68%) | 94 (44%) | N/A | 140 (67%) | 26.6 ± 4.3 | Mechanical ventilation, mortality |
| Maas MB et al. [17] | 1009 | Retrospective cohort | 48.3 ± 17.1 | 4317 (45.9%) | N/A | N/A | 592 (6.3%) | N/A | Severe COVID-19 (respiratory failure) |
| Mazzoleni L et al. [34] 2020 | 40 | Retrospective cohort | 75.3 ± 11.1 | 23 (57.5%) | 37 (92.5%) | N/A | 12 (30%) | 29.7 ± 5.4 | Mortality |
| McCarthy CP et al. [35] 2020 | 247 | Retrospective cohort | 62.3 ± 19.2 | 143 (57.9%) | 128 (51.8%) | 108 (43.7%) | 23 (9.3%) | 28.8 ± 5.8 | ICU admission, mortality |
| Mentzosdous SG et al. [19] 2020 | 124 | Retrospective cohort | 61.5 ± 9.8 | 86 (69.3%) | 72 (58%) | 37 (29.8%) | 9 (7.2%) | 28.3 ± 5.3 | ICU admission |
| Palaiodimos L et al. [36] 2020 | 200 | Retrospective cohort | 62.5 ± 17.4 | 98 (49%) | 152 (76%) | 162 (81%) | N/A | 30.3 ± 6.6 | Mechanical ventilation, mortality |
| Pellaud C et al. [37] 2020 | 196 | Retrospective cohort | 70 ± 14.8 | 119 (61%) | 118 (60%) | 41 (21%) | 25 (13%) | N/A | ICU admission, mortality |
| Suleyman G et al. [38] 2020 | 463 | Retrospective cohort | 57.5 ± 16.8 | 204 (44.1%) | 295 (63.7%) | 262 (57.6%) | 57 (12.3%) | 33 ± 8.5 | ICU admission |
| Vu C et al. [39] 2020 | 60 | Retrospective cohort | 54 ± 10.1 | 40 (66.7%) | 32 (53.3%) | 35 (58.3%) | 2 (3.3%) | N/A | Mortality |
| Xie J et al. [40] 2020 | 287 | Retrospective cohort | 61.5 ± 15.2 | 124 (43.2%) | 230 (80.1%) | 187 (65.2%) | 29 (10.1%) | 33.8 ± 8.5 | ICU admission |

**Table 2**
Newcastle–Ottawa quality assessment of observational studies.

| First author, year | Study design | Selection | Comparability | Outcome | Total score | Result |
|---------------------|--------------|-----------|---------------|---------|-------------|--------|
| Argenziano MG et al. [25] 2020 | Cohort | *** | ** | *** | 8 | Good |
| Cade BE et al. [15] 2020 | Cohort | ** | ** | ** | 7 | Good |
| Cariou B et al. [26] 2020 | Cohort | *** | *** | *** | 9 | Good |
| Dashit H et al. [27] 2020 (pre-print) | Cohort | *** | *** | *** | 7 | Good |
| Dreher M et al. [28] 2020 | Cohort | *** | *** | *** | 8 | Good |
| Feuth T et al. [18] 2020 | Cohort | *** | ** | *** | 8 | Good |
| Goodall JW et al. [29] 2020 | Cohort | ** | ** | ** | 8 | Good |
| Gottlieb M et al. [30] 2020 | Case-control | *** | *** | *** | 8 | Good |
| Ioannou GN et al. [31] 2020 | Cohort | *** | *** | *** | 9 | Good |
| Izquierdo JL et al. [32] 2020 | Cohort | *** | *** | *** | 8 | Good |
| Jimenez E et al. [33] 2020 | Cohort | *** | ** | *** | 8 | Good |
| Kar A et al. [16] 2020 (pre-print) | Cohort | ** | ** | ** | 8 | Good |
| Maas MB et al. [17] | Cohort | ** | ** | ** | 7 | Good |
| Mazzoleni L et al. [34] 2020 | Cohort | *** | *** | *** | 8 | Good |
| McCarthy CP et al. [35] 2020 | Cohort | *** | ** | *** | 8 | Good |
| Mentzosdous SG et al. [19] 2020 | Cohort | ** | ** | ** | 7 | Good |
| Palaiodimos L et al. [36] 2020 | Cohort | ** | ** | ** | 8 | Good |
| Pellaud C et al. [37] 2020 | Cohort | *** | *** | *** | 8 | Good |
| Suleyman G et al. [38] 2020 | Cohort | *** | ** | *** | 8 | Good |
| Vu C et al. [39] 2020 | Cohort | ** | ** | ** | 8 | Good |
| Xie J et al. [40] 2020 | Cohort | *** | ** | *** | 8 | Good |

**means score 2, *** means score 3, **** means score 4.**
| Study or Subgroup        | log(Odds Ratio) | SE    | Weight | Odds Ratio IV, Random, 95% CI | Odds Ratio IV, Random, 95% CI |
|--------------------------|----------------|-------|--------|-------------------------------|-------------------------------|
| **1.1.1 Severe COVID-19**|                |       |        |                               |                               |
| Dreher M et al. 2020     | -0.9628        | 0.8905| 0.4%   | 0.38 [0.07, 2.19]             |                               |
| Gittelb M et al. 2020    | 0.4574         | 0.1899| 4.7%   | 1.58 [1.07, 2.33]             |                               |
| Maas MB et al. 2020      | 0.6831         | 0.093 | 9.5%   | 1.98 [1.65, 2.38]             |                               |
| **Subtotal (95% CI)**    |                |       |        |                               | 1.70 [1.18, 2.45]             |
| Heterogeneity: Tau² = 0.05; Chi² = 4.28, df = 2 (p = 0.12); I² = 53% |                |       |        |                               |                               |
| Test for overall effect: Z = 2.82 (p = 0.005) |                |       |        |                               |                               |
| **1.1.2 ICU admission**  |                |       |        |                               |                               |
| Argenziano MG et al. 2020| 0.295          | 0.4554| 1.3%   | 1.34 [0.55, 3.28]             |                               |
| Cade BE et al. 2020      | 0.4947         | 0.1107| 8.5%   | 1.64 [1.32, 2.04]             |                               |
| Dashti H et al. 2020     | 0.7134         | 0.1586| 6.1%   | 2.04 [1.50, 2.79]             |                               |
| Feuth T et al. 2020      | 0.8755         | 0.9157| 0.3%   | 2.40 [0.40, 14.56]            |                               |
| Izquierdo JL et al. 2020 | -0.5275        | 1.0085| 0.3%   | 0.59 [0.08, 4.26]             |                               |
| Jimenez E et al. 2020    | 1.4713         | 0.443 | 1.3%   | 4.35 [1.83, 10.38]            |                               |
| McCarthy CP et al. 2020  | 0.6931         | 0.448 | 1.3%   | 2.00 [0.83, 4.81]             |                               |
| Mentzoulis SG et al. 2020| 0.3102         | 0.6963| 0.6%   | 1.36 [0.35, 5.34]             |                               |
| Pellaud C et al. 2020    | 0.6111         | 0.4541| 1.3%   | 1.84 [0.76, 4.49]             |                               |
| Sulceman G et al. 2020   | 0.195          | 0.3353| 2.2%   | 1.22 [0.63, 2.34]             |                               |
| Xie J et al. 2020        | 0.5977         | 0.3974| 1.6%   | 1.82 [0.83, 3.96]             |                               |
| **Subtotal (95% CI)**    |                |       |        |                               | 24.7% [1.51, 2.05]            |
| Heterogeneity: Tau² = 0.00; Chi² = 8.55, df = 10 (p = 0.57); I² = 0% |                |       |        |                               |                               |
| Test for overall effect: Z = 7.16 (p < 0.00001) |                |       |        |                               |                               |
| **1.1.3 The Need for Mechanical Ventilation** |                |       |        |                               |                               |
| Cade BE et al. 2020      | 0.4947         | 0.1107| 8.5%   | 1.64 [1.32, 2.04]             |                               |
| Carlu B et al. 2020      | 0.3646         | 0.1912| 4.9%   | 1.44 [0.99, 2.09]             |                               |
| Ioannou GN et al. 2020   | 0.5016         | 0.083 | 10.1%  | 1.65 [1.40, 1.94]             |                               |
| Kar A et al. 2020        | 0.9786         | 0.3038| 2.5%   | 2.66 [1.47, 4.83]             |                               |
| Palaiodimou L et al. 2020| 1.0152         | 0.5605| 0.9%   | 2.76 [1.92, 8.28]             |                               |
| **Subtotal (95% CI)**    |                |       |        |                               | 26.9% [1.48, 1.88]            |
| Heterogeneity: Tau² = 0.00; Chi² = 3.80, df = 4 (p = 0.43); I² = 0% |                |       |        |                               |                               |
| Test for overall effect: Z = 8.37 (p < 0.00001) |                |       |        |                               |                               |
| **1.1.4 Mortality**      |                |       |        |                               |                               |
| Cade BE et al. 2020      | 0.5822         | 0.1593| 6.1%   | 1.79 [1.31, 2.45]             |                               |
| Carlu B et al. 2020      | 0.5933         | 0.2449| 3.5%   | 1.81 [1.12, 2.93]             |                               |
| Dashti H et al. 2020     | 0.8972         | 0.2352| 4.0%   | 2.45 [1.38, 3.81]             |                               |
| Goodall JW et al. 2020   | 0.7023         | 0.4905| 1.1%   | 2.02 [0.77, 5.28]             |                               |
| Ioannou GN et al. 2020   | 0.174          | 0.0737| 10.6%  | 1.19 [1.03, 1.37]             |                               |
| Jimenez E et al. 2020    | 0.3559         | 0.271 | 3.0%   | 1.43 [0.84, 2.43]             |                               |
| Kar A et al. 2020        | 0.8788         | 0.364 | 1.9%   | 2.41 [1.18, 4.91]             |                               |
| Mazzoleni L et al. 2020  | 1.5261         | 0.7595| 0.5%   | 4.60 [1.04, 20.38]            |                               |
| McCarthy CP et al. 2020  | 0.6931         | 0.448 | 1.3%   | 2.00 [0.83, 4.81]             |                               |
| Palaiodimou L et al. 2020| 0.8198         | 0.5583| 0.9%   | 2.27 [0.76, 6.78]             |                               |
| Pellaud C et al. 2020    | 0.2443         | 0.541 | 0.9%   | 1.28 [0.44, 3.69]             |                               |
| Vu C et al. 2020         | 0.0412         | 1.5892| 0.1%   | 1.04 [0.05, 23.48]            |                               |
| **Subtotal (95% CI)**    |                |       |        |                               | 33.0% [1.39, 2.19]            |
| Heterogeneity: Tau² = 0.06; Chi² = 21.10, df = 11 (p = 0.03); I² = 48% |                |       |        |                               |                               |
| Test for overall effect: Z = 4.78 (p < 0.00001) |                |       |        |                               |                               |
| **Total (95% CI)**       |                |       |        |                               | 100.0% [1.55, 1.91]           |
| Heterogeneity: Tau² = 0.02; Chi² = 46.81, df = 10 (p = 0.03); I² = 36% |                |       |        |                               |                               |
| Test for overall effect: Z = 10.06 (p < 0.00001) |                |       |        |                               |                               |
| Test for subgroup differences: Chi² = 0.34, df = 3 (p = 0.95); I² = 0% |                |       |        |                               |                               |

Fig. 2. Forest plot that demonstrates the association of obstructive sleep apnea (OSA) with composite poor outcome and its subgroup which comprises of severe COVID-19, ICU admission, the need for mechanical ventilation, and mortality.
5. Conclusions

Patients with obstructive sleep apnea (OSA) should be given extra care and monitoring to minimize exposure to the virus. Physicians can use the telemedicine-based practice to provide care and evaluations for OSA patients to minimize their visits to the hospitals. Physicians and caregivers should also be engaged in close monitoring of OSA patients with suspected COVID-19, for early diagnosis and treatment to avoid severe infections. Physicians must also consider the diagnosis of OSA in COVID-19 patients where a simple questionnaire can be used without the need for a polysomnography study. STOP-Bang questionnaire which consists of four subjective (STOP: Snoring, Tiredness, Observed apnea, and high blood Pressure), and four demographics items (BANG: BMI, Age, Neck circumference, Gender) provides good results for screening patients with suspected OSA and could identify patients at risk for adverse outcomes [48,49]. Finally, OSA should be considered as an important factor in future risk stratification models for COVID-19.

Author statement

Timotius Ivan Hariyanto: Conceptualization; Data curation; Methodology; Investigation; Validation; Visualization; Writing – original draft; Writing – review & editing. Andree Kurniawan: Conceptualization; Validation; Resources; Writing – original draft; Writing – review & editing; Supervision.

Funding

None.

Conflict of interest

None declared.

Acknowledgment

None.

Conflict of interest

The ICMJE Uniform Disclosure Form for Potential Conflicts of Interest associated with this article can be viewed by clicking on the following link: https://doi.org/10.1016/j.sleep.2021.03.029.

References

[1] Hariyanto TI, Kristine E, Jillian Hardi C, et al. Efficacy of lopinavir/ritonavir compared with standard care for treatment of coronavirus disease 2019 (COVID-19): a systematic review. Infect Disord Drug Targets 2020 Oct 29. https://doi.org/10.2174/1871526520666201029125725.
[2] Kwenandar F, Japar KV, Damay V, et al. Coronavirus disease 2019 and cardiovascular system: a narrative review. Int J Cardiol Heart Vasc 2020;29:100557. https://doi.org/10.1016/j.ijcha.2020.100557.
[3] Hussain A, Mahawar K, Xia Z, et al. Obesity and mortality of COVID-19. Meta-analysis. Obes Res Clin Pract 2020 Jul-Aug;14(4):295–300. https://doi.org/10.1016/j.orcp.2020.07.002.
[4] Hariyanto TI, Kurniawan A. Dyslipidemia is associated with severe coronavirus disease 2019 (COVID-19) infection. Diabetes Metab Syndr 2020;14(5):1463–5. https://doi.org/10.1016/j.dsx.2020.07.054.
[5] Hariyanto TI, Kurniawan A. Statin therapy did not improve the in-hospital outcome of coronavirus disease 2019 (COVID-19) infection. Diabetes Metab Syndr 2020 Aug 26;14(6):1613–5. https://doi.org/10.1016/j.dsx.2020.08.023.
[6] Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis 2020 May;94:91–5. https://doi.org/10.1016/j.ijid.2020.03.017.
[7] Hariyanto TI, Putri C, Arisa J, et al. Dementia and outcomes from coronavirus disease 2019 (COVID-19) pneumonia: a systematic review and meta-analysis. Arch Gerontol Geriatr 2020 Nov 19;91:104299. https://doi.org/10.1016/j.archger.2020.104299.
[8] Hariyanto TI, Kurniawan A. Anemia is associated with severe coronavirus disease 2019 (COVID-19) infection. Transfus Apher Sci 2020 Aug;102926. https://doi.org/10.1016/j.transci.2020.102926.
[9] Hariyanto TI, Kurniawan A. Thyroid disease is associated with severe coronavirus disease 2019 (COVID-19) infection. Diabetes Metab Syndr 2020;14(5):1429–30. https://doi.org/10.1016/j.dsx.2020.07.044.
